This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology (VHIO), part of the Vall d’Hebron Campus at Barcelona, through the spin-off P...
Read moreUn extenso estudio de dieta y salud en EE UU, con más de 130 000 participantes, concluye que consumir este tipo de alimento acelera el deterioro cognitivo y eleva el riesgo de enfermedades como el al...
Read moreIDIBELL researchers identify key factors in Ewing sarcoma metastasis using multi-omics techniques.
Read morePublican un estudio que describe una nueva nanoemulsión capaz de convertir los macrófagos asociados a tumores pro-tumorales en macrófagos proinflamatorios anti-tumorales, reduciendo así la carga t...
Read moreA study published in The Lancet Oncology shows the positive effects of an innovative treatment that combines two drugs, giraredestrant and palbociclib, to stop the proliferation of tumor cells
Read moreEl objetivo principal de este proyecto es mejorar el acceso equitativo a diagnósticos más rápidos y fiables para personas con enfermedades raras y tumores de baja frecuencia de origen genético den...
Read moreThe BLinfoPred initiative seeks to develop and validate predictive tools based on omics technology and liquid biopsy that enable accurate genetic classification of diffuse large B-cell lymphoma (DLBCL...
Read moreThe National Cancer Institute of the National Institutes of Health (NIH) will fund a project that aims to decipher the molecular mechanisms by which hypercaloric diets can cause hepatocellular carcino...
Read moreThe study is based on the analysis of human senescent cells in a specific tumour model — melanoma, which affects skin cells known as melanocytes — and, more specifically, melanocytes exposed to ch...
Read moreSycai Medical software characterizes lesions which enables early diagnosis and automates patient monitoring. For oncologic patients under treatment, it helps healthcare professionals to better underst...
Read moreOryzon Genomics, S.A. announced today that the first patient has been dosed in an investigator-initiated Phase I dose-finding trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in c...
Read moreThis is a prestigious grant awarded by the European Research Council to explore the commercial and societal potential of research projects carried out at European institutions.
Read more